The ICON8 trial evaluated the benefit of dose-dense weekly paclitaxel versus 3-weekly paclitaxel combined with carboplatin in newly diagnosed ovarian cancer. Which conclusion did ICON8 reach, contrasting with the results of the Japanese JGOG-3016 trial?

• A Dose-dense weekly paclitaxel did not significantly improve PFS compared to 3-weekly paclitaxel ✓
• B Dose-dense weekly paclitaxel significantly improved PFS and OS in all patients
• C Dose-dense paclitaxel was inferior due to excess neurotoxicity
• D The combination of weekly carboplatin and paclitaxel had no toxicity advantage

Explanation

ICON8 (UK, 2019) found no significant improvement in progression-free survival with dose-dense weekly paclitaxel (with or without weekly carboplatin) versus 3-weekly carboplatin-paclitaxel, in contrast to the Japanese JGOG-3016 trial (Katsumata et al.) which showed a significant PFS and OS benefit with dose-dense weekly paclitaxel in a predominantly Japanese population. The discrepancy likely reflects pharmacogenomic differences (CYP2C8 polymorphisms affecting paclitaxel clearance) between Asian and Western populations. ICON8 therefore did not establish dose-dense paclitaxel as standard of care in Western populations.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.